Office of Technology Transfer
The Office of Technology Transfer serves as a key component in the overall strategy of the university to be a major player in regional economic development initiatives, commercialization of its technologies and education of the region’s workforce. Our team of professionals can help you navigate the opportunities.
- IP Protection and Compliance
- Licensing and Commercialization
- Marketing Research
- New Ventures
- Entrepreneurs in Residence
Phil Robilotto, DO, MBA
|Phil Robilotto manages the University’s intellectual property, licensing and new business venture efforts. Dr. Robilotto comes to the University with nearly 20 years of clinical practice and pharmaceutical/biotechnology strategic planning and business development experience, most recently with Celera and DuPont Pharmaceuticals. He has led valuation and planning efforts for technology platforms and clinical stage products and has successfully developed, negotiated and executed collaborations across a broad range of life science based technologies with a variety of commercial partners. |
In his current role, he has responsibility for managing the University’s IP portfolio , while leading and expanding its technology assessment, marketing and commercialization efforts. Dr. Robilotto is a licensed physician in the state of Maryland and received his DO from the Chicago College of Osteopathic Medicine. He also holds a BS in Biology from the College of William and Mary and an MBA from Duke University.
Shari Corin, JD, PhD
|Dr. Shari Corin is a patent attorney specializing in biotechnology and the life sciences. Dr. Corin is experienced in all aspects of U.S. and international patent procurement, intellectual property counseling, and portfolio management. Dr. Corin has expertise in a broad range of technologies, including molecular diagnostics, stem cell technologies, pharmaceuticals and biologics, vaccines, screening assays, and medical devices. Before joining the Office of Technology Transfer in September of 2009, she worked in private practice, serving clients from academic, nonprofit, government, and corporate sectors. |
Dr. Corin received an MS in Pathology and a PhD in Biochemistry from the University of Maryland, Baltimore. She performed her postdoctoral research at Harvard Medical School as an American Cancer Society Postdoctoral Fellow. Dr. Corin received a JD from Emory University School of Law, where she also earned a Certificate in Intellectual Property and Technology Commercialization. She is a member of the Georgia Bar and is registered to practice before the United States Patent and Trademark Office.
Robert McCarthy, JD, PhD
|Dr. Robert E. McCarthy is a patent attorney with specialization in biotechnology and life sciences. Dr. McCarthy joined the group in September 2007 and has oversight for all patent related matters for the office. He is experienced in all matters related to intellectual property including patent prosecution, patent licensing, and drafting of various technology transfer agreements. His experience spans the academic, industrial and government sectors.|
Dr. McCarthy earned his BS in Biology, magna cum laude, from Loyola University in Chicago and his MS and PhD degrees in Microbiology from the University of Illinois at Urbana-Champaign. He performed postdoctoral research in the Division of Infectious Diseases at Washington University Medical Center, St. Louis. He earned his law degree from Chicago Kent College of Law. Dr. McCarthy is an inventor on several patents obtained during the time he spent working in industrial research and development. He previously held a position as an adjunct professor of law at the University of Maryland law school teaching a course in patent prosecution. He is a member of the Virginia bar and is registered to practice before the United States Patent and Trademark Office. He holds membership in AIPLA and the American Bar Association.
Nancy Cowger, PhD
|Dr. Nancy Cowger has been an integral member of Office of Technology Transfer since January 2005, negotiating a myriad of agreements involving public-private collaborations, including sponsored research, material transfers, clinical trials, and confidential disclosures to enable unfettered communications. In this role, Nancy has enjoyed establishing good working relationships with faculty, and promoting campus research, in part by her participation in several outreach and training programs over the past two years. Previously, Dr. Cowger was Senior Scientist with a Maryland startup biotechnology company. She was recognized for her leadership role in the planning and execution of the company’s experimental payload on the International Space Station. Dr. Cowger also advanced the company’s goals via supervision of projects, co-writing patent and grant applications, and mentoring junior scientists. Nancy received her doctoral degree in Chemical Engineering from Tulane University, with a Master’s in Molecular & Cell Biology, and is the author of several peer-reviewed publications.|
Camilo Ansarah-Sobrinho, PhD
|Camilo Ansarah-Sobrinho holds a MSc in Microbiology from the University of Sao Paulo, a PhD in Molecular Genetics from George Washington University and has over ten years of experience in biomedical research. Before joining OTT, he spent two years working as a Technology Development Associate with the Office of Technology Development within the National Institute of Allergy and Infectious Disease, where he managed a diverse portfolio of NIH inventions.|
Jeff DiVietro, PhD
|Jeffrey DiVietro holds a PhD in Biomedical Engineering from the University of Virginia. He completed his postdoctoral training at the National Institute of Allergy and Infectious Diseases in a signal transduction lab. Prior to joining OTT as a Technology Licensing Officer, he was a Licensing Associate at Georgetown University where he managed a portfolio of Georgetown inventions. Jeff also worked as a Technology Transfer Specialist with the National Cancer Institute’s Technology Transfer Center.|
Cosimo Fuda, JD, PhD
Technology Licensing Officer
|Cosimo Fuda is a Technology Licensing Officer specializing in pharmaceutical sciences. Cosimo holds a PhD in Chemistry from the University of Notre Dame and received his JD from SUNY Buffalo. He conducted research in synthetic chemistry and pharmaceutical sciences, specializing in antimicrobial development, at Notre Dame and Wayne State University. He performed postdoctoral research in microbiology and immunology at SUNY Buffalo and Northwestern University, Feinberg School of Medicine. He also worked in R&D at GlaxoSmithkline, clerked for Sughrue Mion in its Biotechnology/Chemical Patent Practice Group, and has experience in licensing and technology transfer at the Research Foundation of New York and the University Health Network. He is a member of the New York and the New Jersey bar.|
Linda Yaswen-Corkery, PhD
|Linda Yaswen-Corkery is a Senior Licensing and Commercialization Officer with over 15 years of experience in marketing, business development and strategic planning. Prior to joining the University of Maryland, Linda was the Vice President of Strategic Planning and Chief Compliance Officer for MetaMorphix Inc.; she launched business development initiatives and established key business alliances that facilitated private-public collaboration and secured new business lines. Linda has a PhD in Immunology and Molecular Pathology from the University of Florida, Department of Medicine. She completed further research as an NIH postdoctoral fellow and staff fellow. Linda is a recognized facilitator and negotiator, and has represented business and technology interests at regional and international conferences to secure funding and investor support.|
Jennifer Yoon, PhD
|Jennifer Yoon is OTT’s Technology Licensing Analyst. Jennifer holds a PhD in Physiology from the University of Maryland with a focus on metastatic breast cancer and has recently completed her post-doctoral fellowship at the Greenebaum Cancer Center. In her current role, Jennifer focuses on the evaluation and market positioning of newly disclosed technologies and has responsibility for developing initial marketing strategies for new University inventions.|
Nidhi Rumpal, PhD
|Nidhi Rumpal has joined OTT as a Technology Licensing Analyst. Nidhi holds a PhD from University at Albany, NY and MS from Indian Institute of Science, Bangalore, India. She completed her postdoctoral training in neurology and stem cell biology from Johns Hopkins University. Prior to joining OTT, she received entrepreneurship training from a NSF funded applied training program, INNoVATE. She has provided administrative assistance to the program and lends support towards evaluation of early-stage technologies. As a member of the OTT team, she is interested in working with investigators to seek out opportunities to patent and out-license technologies for commercialization. In her current role, Nidhi focuses on the market evaluation of university technologies, developing an initial marketing strategy and assist with business proposal development.|
Rana Quraishi, PhD
|Rana Quraishi holds a BA in Biology from Columbia University, a MS from Harvard in Physiology and Toxicology, and a PhD in Molecular Biology and Biochemistry, also from Columbia. She has spent much of her career working in life science directed finance, investment and consulting organizations. At the Phoenix Peak Group she advised venture/private equity clients on healthcare and biotechnology investments. At Neeran Associates, she acted as CFO/senior advisor for biotech startup Helicon Therapeutics, successfully developing the company’s business plan, identifying management, and raising several million dollars in initial funding. Earlier in her career Rana worked for Standard and Poor’s GE Capital, and Joseph E. Seagram, where she served as the Director for Strategic Planning and International Treasury. She has served on several for-profit and not for-profit boards, and has also authored the widely read “Market Demand Study for Commercial Biotechnology, Biomedical, and Bioinformatics Facilities in New York City” for the New York City Partnership and Investment Fund.|